University of Basel

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargardt disease and age-related macular degeneration (AMD), bringing decades of expertise in treating retinal diseases, including the two key indications targeted by Belite Bio's lead drug candidate, Tinlarebant. “Dr. Scholl has pioneered some of the most significant ophthalmology advancements of our time, and we are incredibly honored and excited to welcome him as our Chief Medical Officer,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “Dr. Scholl has served as Chair of the Data and Safety Monitoring Board for both our Phase 2 and Phase 3 Stargardt disease trials, and his decision to join Belite further validates our belief in Tinlarebant’s immense potential to improve the lives of patients living with debilitating macular diseases. His leadership, expertise, and commitment to addressing this area of high unmet need has and will continue to be invaluable as we advance our clinical programs.” “I am excited to join Belite Bio at this pivotal time in the Company’s development,” said Dr. Scholl. “I have dedicated my career to improving the lives of people suffering from serious retinal and macular diseases, and I am deeply impressed by Belite Bio’s pioneering approach to developing transformative therapies for Stargardt disease and dry AMD, which have historically lacked effective treatment options. I look forward to working with the team to advance these programs and bring hope to patients around the world.” Dr. Scholl served as the founding and scientific co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Professor of Ophthalmology at the University of Basel, where he also led the Department of Ophthalmology as its Chairman. He currently serves as President of the European Vision Institute as well as Chairman of the largest clinical research network in ophthalmology in Europe, EVICR.net, and its Expert Committee on Retinal Dystrophies. He is also the Founder and President of the Swiss Association for Research in Vision and Ophthalmology (ARVO-SWISS). Dr. Scholl’s distinguished career in academia includes leadership positions at several key academic institutions. Recently, he served as Professor of Ophthalmology and Endowed Chair at the Wilmer Eye Institute of Johns Hopkins University Medical School. At the Johns Hopkins Hospital, he was the Head of the Retinal Degeneration Clinic and the Director of the Visual Neurophysiology Service. For the Wilmer Eye Institute, he also served as the Co-director of the Johns Hopkins Center for Stem Cells and Ophthalmic Regenerative Medicine. Dr. Scholl is the coordinating principal investigator of the largest natural history study of Stargardt disease (ProgStar Study), which enrolled 365 subjects. Throughout his career, he has participated in over 10 clinical studies both in Stargardt disease and AMD, authored over 280 articles and reviews in peer-reviewed journals, and received numerous prestigious awards, including the European Vision Award, the President’s Award of the American Society of Retinal Specialists, the W. Richard Green Award and the Paul Henkind Memorial Award of the Macula Society, the Swiss Alfred-Vogt Award, and the Kupfer award of ARVO. He holds an honorary doctorate from Semmelweis University in Budapest, Hungary, and is Adjunct Professor at the Medical University of Vienna, Austria. Over the course of his 25 years of experience, Dr. Scholl has led and participated in numerous boards and advisory committees. He currently serves on the Scientific Advisory Board of Pro Retina Deutschland, Foundation Fighting Blindness, Erasmus University Medical Center, AIBILI, and the Institut de la Vision (Paris); on the Investment Advisory Board of Droia NV; and the Data Safety Monitoring Board of Roche Holding AG and ViGeneron GmbH. Dr. Scholl graduated from the University of Tübingen, Germany with a Doctor of Medicine (Dr. med.) and Master of Arts. He completed his specialist training at the University Eye Hospital in Tübingen before being awarded a fellowship from the German Research Foundation (DFG) at Moorfields Eye Hospital and Institute of Ophthalmology in London, and a DFG Heisenberg Professorship for Macular Diseases at the Eye Clinic of the University of Bonn, Germany. About Belite Bio Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs such as Stargardt Disease and Geographic Atrophy in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent Stargardt subjects and a Phase 3 study (PHOENIX) in subjects with Geographic Atrophy. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com. Media and Investor Relations Contact:Jennifer Wu : ir@belitebio.com Julie Fallon : belite@argotpartners.com

Dr. Kronenberg brings 25 years of legal experience, with 20 years in the pharmaceutical industry Oliver Strub appointed as Head of Compliance Pratteln, Switzerland, July 31, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the Board of Directors has appointed Dr. Oliver P. Kronenberg as Chief Legal Officer and Corporate Secretary of Santhera Pharmaceuticals AG, effective August 1, 2024. As a member of the executive management team, Dr. Oliver P. Kronenberg will lead the Company's legal strategy and global legal activities, including transactions, corporate governance, and IP. He succeeds Oliver Strub, who remains at Santhera and will assume the newly created role of Head of Compliance, where he will be responsible for overseeing the development, implementation and management of Santhera’s compliance program. “We are pleased to welcome Oliver to Santhera as Chief Legal Officer and as a member of our executive leadership team,” commented Dr. Thomas Meier, Chairman of the Board of Santhera. “His expertise and achievements in key legal areas of the life sciences industry strengthens our leadership team, increasing our expertise in corporate governance and knowledge in the approval and market launch of pharmaceutical products. We extend our deepest thanks to Oliver Strub, who has led Santhera’s legal department since 2006 and will continue as Head of Compliance, where his focus will be on overseeing Santhera’s compliance program.” Dr. Oliver P. Kronenberg is a lawyer with more than 25 years of experience, including over 20 years in the international pharmaceutical industry. Since 2008 he has worked in various roles at Vifor Pharma and its parent company, Galenica. As Head of Legal and Compliance at Vifor Pharma, he was responsible for establishing the legal, IP, and compliance department. In 2013, he was promoted to Group General Counsel of Galenica. After the split of the Galenica Group in April 2017, he returned to Vifor Pharma, becoming Group General Counsel and was appointed member of the executive committee in 2022. Dr. Kronenberg has supported Santhera since April 2024 as interim General Counsel. Dr. Oliver P. Kronenberg commented: “I am excited to be joining Santhera at this important stage of its development, as momentum builds towards the continuous launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy. I look forward to working closely with the executive team and the Board in the months ahead.” Dr. Kronenberg holds a doctorate in law from the University of Basel, an LL.M. degree from the College of Europe in Bruges, Belgium, a degree in Finance for Executives from INSEAD, and an IMD Board Director Diploma. About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), and in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). Santhera has out-licensed rights to vamorolone for North America to Catalyst Pharmaceuticals and for China to Sperogenix Therapeutics. For further information, please visit www.santhera.com. AGAMREE® is a trademark of Santhera Pharmaceuticals. For further information please contact: public-relations@santhera.com orEva Kalias, Head Investor Relations & CommunicationsPhone: +41 79 875 27 80eva.kalias@santhera.com Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # # Attachment 2024 07 31_CLO_e_final

SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, Europe and Israel TEL AVIV, Israel, July 24, 2024 /PRNewswire/ -- SoniVie, which has developed a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of hypertensive disorders, presented on May 15th, 2024 at the EuroPCR conference (Paris, France) the results of its renal denervation REDUCED-1 pilot study, along with a case presentation of the first-in-human treatment with the TIVUS™ Radial Access Catheter. Dr. James Zidar (University of North Carolina, NC) presented the 3-month primary efficacy data from the REDUCED-1 Pilot study (N=40 patients, 25 in US and 15 in Israel): an average -12.0 mmHg reduction in daytime ambulatory systolic blood pressure (ASBP) comparing baseline to 3-month was obtained, with 78.4% of patients being responders (≥5mm reduction in daytime ASBP). The responder ASBP 3-month average reduction was -16.2mmHg. No device related adverse events were reported in the 1-month primary safety endpoint analysis, and efficacy data are sustained at 6-month follow-up. "This is the first no-touch RDN device that is not required to be in contact with the renal artery vessel wall, which is unique as the other RDN technologies to date require contact" commented the EuroPCR panel of discussants and renal denervation experts. Professor Michael Jonas (Kaplan, Israel) introduced the 4Fr Rapid Exchange Radial Access TIVUS™ Catheter as the newest evolution of RDN technologies and presented the first-in-human clinical case performed. More recently, on July 17th, 2024, the FDA approved the THRIVE study, an international, multicentre, randomized, double blind, sham-controlled study, designed to demonstrate the adjunctive effectiveness and safety of the TIVUS™ System in hypertensive subjects while subjects are maintained off-antihypertensive medications for a 4-week wash-out period before RDN/Sham procedure and 2 months after procedure. At 2 months after procedure, subjects with uncontrolled hypertension are put back on antihypertensive medication according to a medication escalation protocol. Unblinding will be performed at 6 months. Uncontrolled sham subjects can crossover to TIVUS™ at 6-months. The THRIVE Study is led by a Global Steering Committee comprised of Dr. Ajay Kirtane (Columbia University Medical Center, New York City, NY), Dr. Michel Azizi (George Pompidou Hospital, Paris, France) and Dr. Felix Mahfoud (University of Basel, Basel, Switzerland). "The SoniVie clinical operations teams throughout US, Europe and Israel are now supporting sites, physicians and patients participating in the global pivotal THRIVE Study, anticipating enrollment of the first patient in the fourth quarter of 2024", says Tomaso Zambelli, Chief Executive Officer, SoniVie. Renal Denervation with TIVUS™ is a minimally invasive procedure that uses a high-frequency non-focused ultrasound energy catheter which does not anchor to the vessel wall during treatment to ablate nerves in the surrounding tissue located along the renal arteries, thereby reducing sympathetic activity which lowers blood pressure. About SoniVie SoniVie is a medical device company developing the TIVUS™ System, the only platform denervation technology with active development programs in three therapeutic areas: renal artery denervation for resistant hypertension, pulmonary artery denervation for pulmonary hypertension, and total lung denervation for chronic obstructive pulmonary disease with chronic bronchitis. These diseases affect millions of patients around the world. The company's offices are located in Rehovot, Israel and in Minneapolis, MN, USA Contact: Tomaso Zambelli CEO, Sonivie [email protected] SOURCE SoniVie